LCGC Home

LIMR Chemical Genomics Center (LCGC) is a biotech company that was created to fill a major gap in technology by providing access to large compound libraries for high-throughput screening. LCGC is efficiently storing and arraying hundreds of thousands of compounds that can be used to evaluate new drug targets.

Besides a dramatic head start in erecting the infrastructure necessary to execute its business plan, LCGC has the full backing of Lankenau Institute for Medical Research (LIMR), its lone shareholder. Founded in 1927, Lankenau Institute for Medical Research (LIMR) is an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Medical Center. LIMR is one of the few freestanding, hospital-associated medical research centers in the nation. LIMR’s current facility houses more than 120 individuals including a team of 18 principal investigators and more than 30 affiliated clinical and nursing faculty. The staff is dedicated to advancing an understanding of the causes of disease in order to help improve diagnosis and find new ways to treat and prevent them.

Because of LIMR’s emphasis on the target pathways of disease, LIMR is aware of the constraints that burden the vast majority of lead compound discovery researchers throughout the world. These limitations in the areas of compound access, storage, handling, and time-consuming screens, were very clear to Dr. Melvin Reichman as he developed the technology that is the infrastructure of LCGC. LCGC was formed as a Pennsylvania C-Corporation in 2007. It stands as a wholly-owned subsidiary of the nonprofit Lankenau Institute for Medical Research (LIMR). Forming a corporation for one of its projects was a very unusual step for LIMR. However, the potential of the LCGC project is tremendous, and LIMR wanted to ensure its potential by structuring the organization in a form that would optimize its ability to accept outside capital.

Please browse our website for more information or download our brochure here.